Equities

Humacyte Inc

HUMA:NSQ

Humacyte Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.05
  • Today's Change-0.150 / -2.08%
  • Shares traded1.17m
  • 1 Year change+104.64%
  • Beta1.5918
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Humacyte, Inc. is engaged in the development and manufacturing of off-the-shelf, universally implantable, bioengineered human tissues. The Company is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The Company has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. It is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Company’s scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.

  • Revenue in USD (TTM)0.00
  • Net income in USD-105.70m
  • Incorporated2020
  • Employees183.00
  • Location
    Humacyte Inc2525 East North Carolina Highway 54DURHAM 27713United StatesUSA
  • Phone+1 (919) 313-9633
  • Fax+1 (302) 655-5049
  • Websitehttps://humacyte.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Viridian Therapeutics Inc288.00k-218.13m793.95m96.00--2.07--2,756.78-4.50-4.500.00589.130.0006--2.503,063.83-42.89-55.59-45.38-60.32-----75,737.84-5,678.12----0.0337---82.28-48.16-83.05--15.08--
Cogent Biosciences Inc0.00-212.17m805.54m164.00--4.02-----2.47-2.470.004.420.00----0.00-57.40-49.53-62.27-54.94-------1,684.44----0.00-------37.20--38.48--
Aurinia Pharmaceuticals Inc191.41m-62.56m808.06m300.00--2.26--4.22-0.4363-0.43631.342.500.39530.60087.98638,023.30-12.92-25.97-14.63-28.2488.78---32.69-137.645.05--0.1843--30.95227.9027.88--57.11--
Arcturus Therapeutics Holdings Inc124.53m-107.30m834.89m180.00--3.16--6.70-4.02-4.024.669.810.2799--2.08691,811.10-24.12-19.66-31.37-24.90-----86.16-77.55----0.00---19.0360.31-417.95--14.44--
ARS Pharmaceuticals Inc10.00k-49.70m839.11m24.00--3.74--83,911.29-0.5198-0.51980.00012.320.00004----416.67-19.93-20.37-20.48-21.32-----496,960.00-17,491.75----0.00---97.72---56.75---17.18--
Humacyte Inc0.00-105.70m839.54m183.00--32.10-----1.01-1.010.000.21960.00----0.00-61.38---68.92-------------61.500.4145---100.00---825.83------
Stoke Therapeutics Inc7.85m-108.53m846.95m110.00--5.38--107.96-2.42-2.420.17473.020.0322--31.1971,318.18-44.57-31.62-51.70-33.92-----1,383.40-1,775.50----0.00---29.22---3.59--11.56--
Prime Medicine Inc591.00k-204.50m853.42m234.00--3.50--1,444.03-2.17-2.170.00622.030.0019----2,525.64-65.09---70.51-------34,601.86------0.00-------39.52------
USANA Health Sciences, Inc.900.45m61.94m856.51m1.80k14.031.7111.490.95123.203.2046.5626.251.462.73--500,250.0010.0316.2312.4921.7580.9881.426.888.963.20--0.00260.00-7.77-4.98-8.02-12.764.86--
89bio Inc0.00-165.03m862.83m70.00--1.64-----2.01-2.010.005.360.00----0.00-30.80-45.50-32.70-49.31------------0.0466-------39.37---36.58--
OPKO Health Inc799.60m-252.43m871.24m3.93k--0.6955--1.09-0.3427-0.34271.081.800.38597.536.87203,461.30-12.18-7.14-13.58-8.1432.6334.42-31.56-13.831.58-4.960.2217---14.01-2.7042.49---10.19--
Rapport Therapeutics Inc0.00-51.31m888.81m58.00---------1.45-1.450.005.52------0.00--------------------0.00-------226.57------
Ocular Therapeutix Inc59.84m-115.27m890.61m267.00--2.18--14.88-1.09-1.090.63352.640.17932.232.51224,127.30-34.54-46.70-37.58-54.1890.9989.36-192.62-228.6521.29-9.100.1401--13.4996.60-13.65--26.37--
Immunome Inc12.68m-232.03m894.74m55.00--3.12--70.55-5.49-5.490.42734.780.069----230,600.00-126.15-94.54-148.61-112.66-----1,829.44-1,403.15----0.00-------184.68--29.52--
Data as of Jun 14 2024. Currency figures normalised to Humacyte Inc's reporting currency: US Dollar USD

Institutional shareholders

14.80%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 20244.43m3.72%
The Vanguard Group, Inc.as of 31 Mar 20243.91m3.28%
AIGH Capital Management LLCas of 31 Mar 20242.16m1.81%
Sio Capital Management LLCas of 31 Mar 20242.00m1.68%
Geode Capital Management LLCas of 31 Mar 20241.35m1.13%
SSgA Funds Management, Inc.as of 31 Mar 20241.21m1.02%
Monashee Investment Management LLCas of 31 Mar 20241.00m0.84%
Prescott General Partners LLCas of 31 Mar 2024568.25k0.48%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024534.01k0.45%
Charles Schwab Investment Management, Inc.as of 31 Mar 2024473.77k0.40%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.